Compare DAN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | NAMS |
|---|---|---|
| Founded | 1904 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.1B |
| IPO Year | 2003 | 2022 |
| Metric | DAN | NAMS |
|---|---|---|
| Price | $30.59 | $23.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $40.60 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 264.10 | 32.81 |
| EPS | ★ 9.93 | N/A |
| Revenue | ★ $7,500,000,000.00 | $22,503,000.00 |
| Revenue This Year | $1.89 | $17.96 |
| Revenue Next Year | $4.59 | $540.65 |
| P/E Ratio | $3.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.74 | $23.05 |
| 52 Week High | $39.56 | $42.21 |
| Indicator | DAN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 28.37 |
| Support Level | $28.68 | N/A |
| Resistance Level | $31.83 | $37.29 |
| Average True Range (ATR) | 0.91 | 1.16 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 47.99 | 0.19 |
Dana Inc is provider of products to virtually every vehicle manufacturer in the world. Its technologies include drive systems (axles, driveshafts and transmissions); electrodynamic technologies (motors, inverters, software and control systems, battery-management systems, and fuel cell plates); sealing solutions (gaskets, seals, cam covers, and oil pan modules); thermal-management technologies (transmission and engine oil cooling, battery and electronics cooling, charge air cooling, and thermal-acoustical protective shielding); and digital solutions (active and passive system controls and descriptive and predictive analytics). The company has two operating segments: Light Vehicle and Commercial Vehicle. The Light Vehicles segment generates the majority of revenue.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.